Current Infectious Disease Reports

, Volume 7, Issue 2, pp 125–131 | Cite as

A virus-based vaccine may prevent cervical cancer

  • Patti E. Gravitt
  • Keerti V. Shah


High-risk human papillomaviruses (HPVs) are now recognized as the etiologic agents of invasive cervical cancer, a major cancer in women. A single HPV type (type 16) is responsible for about 50% of the cancers. The major capsid protein of papillomaviruses, L1, when expressed by recombinant DNA technology, has the intrinsic ability to assemble into virus-like particles (VLPs). In a recent study, a vaccine based on HPV 16 VLPs was tested in a placebo-controlled proof-of-principle trial in young women in the United States. The vaccine was found to prevent 100% of incident persistent HPV 16 infections and HPV 16-associated cervical intraepithelial neoplasia. These results offer promise that cervical cancer will be preventable by an HPV-based vaccine. Studies planned or in progress are examining the efficacy of the vaccine in men, in HIV-infected individuals, and in other parts of the world. Attempts are being made to prepare vaccines that can be administered more easily to large populations.


Cervical Cancer Cervical Intraepithelial Neoplasia Natl Cancer Inst Invasive Cervical Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pisani P, Parkin DM, Munoz N, Ferlay J: Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997, 6:387–400.PubMedGoogle Scholar
  2. 2.
    Huang K, Lin S Nationwide vaccination: a success story in Taiwan. Vaccine 2000, 18(Suppl 1):S35-S38.PubMedCrossRefGoogle Scholar
  3. 3.
    Kao JH, Chen DS: Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395–403.PubMedCrossRefGoogle Scholar
  4. 4.
    Walboomers JMM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Munoz N, Bosch FX, Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518–527.PubMedCrossRefGoogle Scholar
  6. 6.
    Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645–1651. This article provides a succinct and clear account of the “proof of concept” trial of the HPV 16 VLP Merck vaccine.PubMedCrossRefGoogle Scholar
  7. 7.
    Lowy DR, Howley PM: Papillomaviruses. In Fields Virology. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins; 2001:2231–2264.Google Scholar
  8. 8.
    Ho GY, Bierman R, Beardsley L, et al.: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423–428.PubMedCrossRefGoogle Scholar
  9. 9.
    Franco EL, Villa LL, Sobrinho JP, et al.: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415–1423.PubMedCrossRefGoogle Scholar
  10. 10.
    Galloway DA: Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003, 3:469–475.PubMedCrossRefGoogle Scholar
  11. 11.
    Schiller JT, Lowy DR: Preventive human papillomavirus vaccines. In Cervical Cancer: From Etiology to Prevention. Edited by Rohan T, Shah KV. Dordrecht: Kluwer Academic Publishers; 2004:325–343. This article provides an excellent discussion of the considerations related to the use of HPV vaccines in different populations.CrossRefGoogle Scholar
  12. 12.
    Lowy DR, Frazer IH: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003, 31:111–116. This article, similar to the study by Schiller et al. [11] provides an excellent discussion of the considerations related to the use of HPV vaccines in different populations.PubMedGoogle Scholar
  13. 13.
    Shah KV, Howley PM: Papillomaviruses. In Virology. Edited by Fields BN, Knipe DM, Howley PM, et al. Philadelphia: Lippincott-Raven; 1996:2077–2109.Google Scholar
  14. 14.
    Kirnbauer R, Booy F, Cheng N, et al.: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992, 89:12180–12184.PubMedCrossRefGoogle Scholar
  15. 15.
    Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993, 67:315–322.PubMedGoogle Scholar
  16. 16.
    Zhou J, Stenzel DJ, Sun XY, Frazer IH: Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 1993, 74:763–768.PubMedCrossRefGoogle Scholar
  17. 17.
    Breitburd F, Kirnbauer R, Hubbert NL, et al.: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959–3963.PubMedGoogle Scholar
  18. 18.
    Christensen ND, Reed CA, Cladel NM, et al.: Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996, 70:960–965.PubMedGoogle Scholar
  19. 19.
    Suzich JA, Ghim SJ, Palmer-Hill FJ, et al.: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92:11553–11557.PubMedCrossRefGoogle Scholar
  20. 20.
    Kirnbauer R, Chandrachud LM, O’Neil BW, et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219:37–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Harro CD, Pang YY, Roden RB, et al.: Safety and immunogenicity trial in adult volunteers of an HPV 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93:284–292.PubMedCrossRefGoogle Scholar
  22. 22.
    Harper DM, Franco EL, Wheeler C, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757–1765. This article provides evidence that a bivalent HPV 16/18 vaccine prevents infections with both of these oncogenic viruses.PubMedCrossRefGoogle Scholar
  23. 23.
    Stone KM, Karem KL, Sternberg MR, et al.: Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002, 186:1396–1402.PubMedCrossRefGoogle Scholar
  24. 24.
    Nardelli-Haefliger D, Wirthner D, Schiller JT, et al.: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003, 95:1128–1137.PubMedCrossRefGoogle Scholar
  25. 25.
    Clifford GM, Smith JS, Plummer M, et al.: Human papilloma-virus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63–73. This article discusses the relative importance of different HPV types for cervical cancer in different regions of the world.PubMedCrossRefGoogle Scholar
  26. 26.
    Roden RB, Yutzy WH, Fallon R, et al.: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254–257.PubMedCrossRefGoogle Scholar
  27. 27.
    Kawana K, Yasugi T, Kanda T, et al.: Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 2003, 21:4256–4260.PubMedCrossRefGoogle Scholar
  28. 28.
    Pinto LA, Edwards J, Castle PE, et al.: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003, 188:327–338.PubMedCrossRefGoogle Scholar
  29. 29.
    Greenstone HL, Nieland JD, de Visser KE, et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998, 95:1800–1805.PubMedCrossRefGoogle Scholar
  30. 30.
    Liu XS, Liu WJ, Zhao KN, et al.: Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol 2002, 80:21–29.PubMedCrossRefGoogle Scholar
  31. 31.
    Muller M, Zhou J, Reed TD, et al.: Chimeric papillomavirus-like particles. Virology 1997, 234:93–111.PubMedCrossRefGoogle Scholar
  32. 32.
    Rose RC, Lane C, Wilson S,et al.: Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 1999, 17:2129–2135.PubMedCrossRefGoogle Scholar
  33. 33.
    Nardelli-Haefliger D, Roden RB, Benyacoub J, et al.: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997, 65:3328–3336.PubMedGoogle Scholar
  34. 34.
    Biemelt S, Sonnewald U, Galmbacher P, et al.: Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003, 77:9211–9220.PubMedCrossRefGoogle Scholar
  35. 35.
    Warzecha H, Mason HS, Lane C, et al.: Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003, 77:8702–8711.PubMedCrossRefGoogle Scholar
  36. 36.
    Gillison ML, KochWM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709–720.PubMedCrossRefGoogle Scholar
  37. 37.
    Goldie SJ, Kohli M, Grima D, et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604–615.PubMedCrossRefGoogle Scholar
  38. 38.
    Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781–789.PubMedCrossRefGoogle Scholar
  39. 39.
    Goldie SJ, Grima D, Kohli M, et al.: A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106:896–904.PubMedCrossRefGoogle Scholar
  40. 40.
    Bosch FX, Manos MM, Munoz N, et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796–802.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Patti E. Gravitt
  • Keerti V. Shah
    • 1
  1. 1.Department of Molecular Microbiology and ImmunologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations